Enanta Pharma (ENTA) Tops Q1 EPS by 40c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips below $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2017
February 7, 2018 4:01 PM ESTWebcast and Conference Call today at 4:30 p.m. ET
Total revenue for the quarter was $38.1 million Net income for the quarter was $11.7 million, or $0.59 per diluted common share Cash and marketable securities totaled $297.5 million at December 31, 2017 and include the milestone payment of $15.0 million received following reimbursement approval of AbbVies MAVIRET (glecaprevir/pibrentasvir) in Japan Recruitment initiated in Phase 2, ARGON-1 study of EDP-305 in NASHWATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:... More
